REFERENCES
- Rickert CH, Paulus W. Epidemiology of central nervous system tumors in
childhood and adolescence based on the new WHO classification.Child’s Nerv Syst. 2014;17(9):503-511.
- Maraka S, Janku F. BRAF alterations in primary brain tumors.Discov Med. 2018;26:51-60.
- Kurani H, Gurav M, Shetty O, et al. Pilocytic astrocytomas: BRAFV600E
and BRAF fusion expression patterns in pediatric and adult age groups.Child’s Nerv Syst. 2019;35(9):1525-1536.
- Hargrave DR, Bouffet E, Tabori U, et al. Efficacy and safety of
dabrafenib in pediatric patients with BRAF V600 mutation-positive
relapsed or refractory low-grade glioma: results from a phase I/IIa
study. Clin Cancer Res. 2019;25(24):7303-7311.
- Bellón T, Lerma V, González-Valle O, González Herrada C, J de Abajo F.
Vemurafenib-induced toxic epidermal necrolysis: possible
cross-reactivity with other sulfonamide compounds. Br J
Dermatol . 2016;174(3):621-624.
- Song H, Zhong CS, Kieran MW, Chi SN, Wright KD, Huang JT. Cutaneous
reactions to targeted therapies in children with CNS tumors: A
cross-sectional study. Pediatr Blood Cancer . 2019;66(6):e27682.
- Marks AM, Bindra RS, DiLuna ML, et al. Response to the BRAF/MEK
inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E
mutated anaplastic ganglioglioma intolerant to vemurafenib.Pediatr Blood Cancer. 2017;65(5):e26969.
- Jeudy G, Dalac-Rat S, Bonniaud B, et al. Successful switch to
dabrafenib after vemurafenib-induced toxic epidermal necrolysis.Br J Dermatol. 2015;172(5):1454-1455.
- Bar-Sela G, Abu-Amna M, Hadad S, Naim N, Shahar E. Successful
desensitization protocol for hypersensitivity reaction probably caused
by dabrafenib in a patient with metastatic melanoma. Jpn J Clin
Oncol . 2015;45(9):881-883.
- Tahseen AI, Patel NB. Successful dabrafenib transition after
vemurafenib-induced toxic epidermal necrolysis in a patient with
metastatic melanoma. JAAD Case Reports . 2018;4(9):930-933.
- Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, Jakacki
R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM. Carboplatin
and vincristine chemotherapy for children with newly diagnosed
progressive low-grade gliomas. J Neurosurg. 1997;86(5): 747-54.
- Packer, Jakacki R, Horn M, et al. Objective response of multiply
recurrent low-grade gliomas to bevacizumab and irinotecan.Pediatr Blood Cancer . 2009;52(7):791-795.
- Croce L, Coperchini F, Magri F, Chiovato L, Rotondi M. The
multifaceted anti-cancer effects of BRAF-inhibitors.Oncotarget . 2019;10(61):6623-6640.
- Upadhyaya SA, Robinson GW, Harreld JH, et al. Marked functional
recovery and imaging response of refractory optic pathway glioma to
BRAFV600E inhibitor therapy: a report of two cases. Childs Nerv
Syst. 2018;34(4):605-610.
- Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in
drug hypersensitivity reacts to sulfasalazine and sulfamethoxazole.Int Arch Allergy Immunol . 2010;153(2):152-156.
- Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and
cobimetinib in BRAF-mutated melanoma. N Engl J Med.2014(20);371:1867-1876.
- Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK
inhibition versus BRAF inhibition alone in melanoma. N Engl J
Med. 2014;371(20):1877-1888.
- Robert C, Karaszewska B, Schachter J, et al. Improved overall survival
in melanoma with combined dabrafenib and trametinib. N Engl J
Med . 2014;(1)372:30-39.
FIGURE LEGEND
FIGURE 1 Fat-saturated axial T2 weighted image (A) showing
tortuosity and thickening of the intraorbital portions of the optic
nerves (arrows) and a postcontrast axial T1-weighted image (B)
demonstrating enhancement in and along the enlarged prechiasmatic optic
nerves, optic chiasm, and proximal optic tracts (arrows), consistent
with an optic pathway glioma at 5 months of age. Postcontrast T2 FLAIR
image (C) before receiving targeted therapy at 7 years of age showing
expansile hyperintensity in the bilateral optic tracts (arrows) and an
increase in abnormal signal in the region of the hypothalamus and
anterior commissure (large arrow) with a postcontrast axial T1-weighted
image (D) showing increased enhancement in the bilateral optic tracts
and in the optic chiasm (arrows). Postcontrast axial T2 FLAIR image (E)
showing decreased expansile hyperintensity in portions of the bilateral
optic tracts (arrows) and postcontrast axial T1-weighted image (F)
demonstrating near complete to complete resolution of enhancement in the
optic tracts and optic chiasm (arrows) after 8 weeks of targeted
therapy. Postcontrast axial T2 FLAIR image (G) demonstrating continued
decreased expansile hyperintensity in the bilateral optic tracts and in
the region of the anterior commissure and hypothalamus (arrows) and a
postcontrast axial T1-weighted image (H) showing resolution of
enhancement in the optic tracts (arrows) after 18 months of targeted
therapy.